within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC16_Guselkumab;
model Guselkumab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AC16;

  annotation(Documentation(
    info ="<html><body><p>Guselkumab is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor. It is approved for the treatment of moderate-to-severe plaque psoriasis in adults and for psoriatic arthritis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis following subcutaneous administration. Population PK model from pooled clinical trials (brodalumab comparator group) with typical adult subject (mean body weight 90 kg).</p><h4>References</h4><ol><li><p>Chen, Y, et al., &amp; Sharma, A (2022). Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis. <i>Clinical and translational science</i> 15(3) 749–760. DOI:<a href=&quot;https://doi.org/10.1111/cts.13197&quot;>10.1111/cts.13197</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34854241/&quot;>https://pubmed.ncbi.nlm.nih.gov/34854241</a></p></li><li><p>Zhu, Y, et al., &amp; Sharma, A (2020). Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. <i>Clinical and translational science</i> 13(6) 1217–1226. DOI:<a href=&quot;https://doi.org/10.1111/cts.12807&quot;>10.1111/cts.12807</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32407591/&quot;>https://pubmed.ncbi.nlm.nih.gov/32407591</a></p></li><li><p>Boehncke, WH, et al., &amp; Nissen, MJ (2021). Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. <i>Expert review of clinical immunology</i> 17(1) 5–13. DOI:<a href=&quot;https://doi.org/10.1080/1744666X.2020.1857733&quot;>10.1080/1744666X.2020.1857733</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33251833/&quot;>https://pubmed.ncbi.nlm.nih.gov/33251833</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Guselkumab;
